When administration is with insulin: In line with NICE NG28, diabetes specialist initiation advice/recommendation should be sought when initiating GLP1 agonists in combination with insulin. The CareSens N meets and exceeds the 2013 ISO standards for blood glucose meter accuracy with 99% of results meeting the 2013 accuracy criteria. Sample loading – avoid spoiled tests Transfer to prescribing to Primary Care should not happen until specialists can demonstrate a reduction in nocturnal hypoglycaemia(e.g. after 3-4 months) You can use blood samples taken your fingertip, palm or forearm. A small sample of blood is required and your result is displayed in less than 5 seconds. For your patients with diabetes who are currently prescribed Apidra®: A guide on how to use Apidra®.

for treating chronic heart failure with reduced ejection fraction as per NICE TA679: Dapagliflozin for treating chronic heart failure with reduced ejection fraction The CareSens N meter features a large display and no-skid rubber pads on the meter, so it’s easy to handle.Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a Specialist. For your patients with diabetes who are currently prescribed Lantus ®: A step-by-step guide on how to use Lantus® SoloStar. The CareSens N Blood Glucose Monitor offers easy and accurate testing and there’s no coding required. MHRA Alert: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness

For your patients with diabetes who are currently prescribed Toujeo® SoloStar: A guide on how to use Toujeo ® SoloStar. MHRA Alert: SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019) NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes

Sample loading – avoid spoiled tests

The managed introduction of biosimilar Insulin Glargine (Semglee®▼) for patients with Type 2 Diabetes

Victoza (liraglutide) 1.2mg daily dose is appropriate for most patients . Victoza 1.8mg daily is NON-FORMULARY. Patients requiring doses higher than Victoza (liraglutide) 1.2mg should be switched to an alternative GLP-1 receptor agonist e.g. Trulicity (dulaglutide) 1.5 mg weekly or Ozempic (semaglutide) 1mg weekly.

Thin lancets and 1,000 test memory

Patients are required to wait at least 30 minutes before eating/drinking or taking other oral medicinal products. Waiting less than 30 minutes decreases absorption. Training on the correct use, storage and recording of the readings should be provided by the issuing clinician The use of Liraglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management servicewith a commercial agreement in place. Using the latest technology, CareSens N monitors use a highly specific glucose oxidase reagent that will only measure glucose.

To avoid the use of an insulin pump in patients with Type 1 diabetes who have nocturnal/severe hypoglycaemia as defined in NICE TA 151 OR recurrent DKA despite good compliance with current insulin regime It should be swallowed whole with a sip of water (up to half a glass of water equivalent to 120 ml). Pioglitazone should not be used in people who have heart failure or who are at higher risk of fracture. Continue Pioglitazone therapy only if there is a reduction of ≥0.5 percentage points in HbA1c in 6 months. Monitor for liver toxicity. There is risk of bladder cancer with pioglitazone. Do not use in active bladder cancer or a past history of bladder cancer, or in those who have uninvestigated macroscopic haematuria. Assess risks for bladder cancer after 3-6months of starting pioglitazone. Refer to current BNF for full contraindications and interactionsTHIS IS FOR DIABETES ONLY . Prescribe by brand (Victoza ® ) to avoid patients inadvertently receiving a different product licensed for obesity.